Company news: Janssen, Zeno Group

Share this article:
Janssen is reassuming ex-US marketing rights for its Caeylx/Doxil cancer treatment. Merck & Co. has marketed the drug abroad since 1996. That deal expires at the end of the year, and marketing rights for the drug will revert to Janssen subsidiary ALZA Corp. Janssen currently markets the product in the US, Japan and Israel under the Doxil brand.

Zeno Group named former Burson-Marsteller healthcare head Ame Wadler managing director for health and strategic planning. Wadler joins the firm from MWW Group, where she was EVP, chief management officer. Before that, she was chief strategic officer at Burson and chairman of the global healthcare practice, having joined that firm from Zeno Group parent Edelman.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.